Lamisil Solution, 1%

Company
Novartis

Approval Status
Approved March 2001

Treatment for
Dermatologic infections

Possible similar drugs
Lamisil; Lamisil; Lamisil

Areas
Dermatology / Plastic Surgery

Lamisil Solution, 1% is a synthetic antifungal compound approved for the topical treatment of tinea (pityriasis) versicolor due to Malassezia furfur, and tinea pedis (athlete's foot), tinea cruris (jock itch), or tinea corporis (ringworm), due to Trichophyton rubrum, Trichophyton mentagrophytes, or Epidermaphyton floccosum.

Lamisil Solution, 1% is designed for one week usage and is administered to the infected area once or twice daily, depending on indication.

The effectiveness of Lamisil Solution, 1% was evaluated in separate eight week placebo-controlled trials for tinea (pityriasis) versicolor, tinea pedis, and tinea corporis/cruris, involving a total of 898 subjects. In the majority of pateints, relief of symptoms began within the one week treatment period and continued improvement was recorded over the following seven weeks. (from Lamisil Solution, 1% Prescribing Information)

Adverse events associated with the use of terbinafine hydrochloride may include (but are not limited to) the following:


  • site irritation
  • itching
  • skin exfoliation
  • erythematous rash

Lamisil Solution, 1% (terbinafine hydrochloride solution) is a synthetic allyamine derivative. Terbinafine hydrochloride is thought to act by inhibiting the epoxidation of squalene, thus blocking the biosysnthesis of ergosterol, an essential component of fungal cell membranes. Depending on the concentration of the drug and the fungal species being tested in vitro, terbinafine hydrochloride may be fungicidal. (from Lamisil Solution, 1% Prescribing Information)

For additional information on Lamisil Solution, 1%, please visit Novartis.

Lamisil_solution_1 Drug Information

The Lamisil_solution_1 drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Scroll to top